Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Activation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasia.

Madigan AA, Sobek KM, Cummings JL, Green WR, Bacich DJ, O'Keefe DS.

Genes Immun. 2012 Oct;13(7):566-72. doi: 10.1038/gene.2012.40. Epub 2012 Sep 6.

2.

Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis.

Luo J, Dunn T, Ewing C, Sauvageot J, Chen Y, Trent J, Isaacs W.

Prostate. 2002 May 15;51(3):189-200.

PMID:
11967953
3.

Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays.

Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, Kakehi Y, Getzenberg RH.

Proc Natl Acad Sci U S A. 2002 May 28;99(11):7598-603.

4.

Human endogenous retrovirus expression is inversely related with the up-regulation of interferon-inducible genes in the skin of patients with lichen planus.

Nogueira MA, Gavioli CF, Pereira NZ, de Carvalho GC, Domingues R, Aoki V, Sato MN.

Arch Dermatol Res. 2015 Apr;307(3):259-64. doi: 10.1007/s00403-014-1524-0. Epub 2014 Nov 11.

PMID:
25384438
5.

Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia.

Cohen P, Peehl DM, Baker B, Liu F, Hintz RL, Rosenfeld RG.

J Clin Endocrinol Metab. 1994 Nov;79(5):1410-5.

PMID:
7525636
6.

Microwave thermotherapy for benign prostatic hyperplasia.

Hoffman RM, Monga M, Elliott SP, Macdonald R, Langsjoen J, Tacklind J, Wilt TJ.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD004135. doi: 10.1002/14651858.CD004135.pub3. Review.

PMID:
22972068
7.

Microwave thermotherapy for benign prostatic hyperplasia.

Hoffman RM, Monga M, Elliot SP, Macdonald R, Wilt TJ.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004135. Review. Update in: Cochrane Database Syst Rev. 2012;9:CD004135.

PMID:
17943811
8.

B-cell agonists up-regulate AID and APOBEC3G deaminases, which induce IgA and IgG class antibodies and anti-viral function.

Seidl T, Whittall T, Babaahmady K, Lehner T.

Immunology. 2012 Mar;135(3):207-15. doi: 10.1111/j.1365-2567.2011.03524.x.

9.

Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network.

Lin-Tsai O, Clark PE, Miller NL, Fowke JH, Hameed O, Hayward SW, Strand DW.

Prostate. 2014 May;74(6):669-79. doi: 10.1002/pros.22785. Epub 2014 Feb 5.

10.

Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.

Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, Terashima M, Fujime M, Igawa M, Dahiya R.

Clin Cancer Res. 2005 Feb 1;11(3):1028-36.

12.

PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.

Koch P, Petri M, Paradowska A, Stenzinger A, Sturm K, Steger K, Wimmer M.

Prostate. 2009 Dec 1;69(16):1751-62. doi: 10.1002/pros.21025.

PMID:
19691131
13.

Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment.

Mobley D, Feibus A, Baum N.

Postgrad Med. 2015 Apr;127(3):301-7. doi: 10.1080/00325481.2015.1018799. Review.

PMID:
25823641
14.

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.

Roehrborn CG, Siami P, Barkin J, DamiĆ£o R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group.

Eur Urol. 2010 Jan;57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19. Erratum in: Eur Urol. 2010 Nov;58(5):801.

PMID:
19825505
15.

Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach.

Fromont G, Chene L, Latil A, Bieche I, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Cussenot O.

J Urol. 2004 Oct;172(4 Pt 1):1382-5.

PMID:
15371850
16.

Myosin heavy chain gene expression in normal and hyperplastic human prostate tissue.

Lin VK, Wang D, Lee IL, Vasquez D, Fagelson JE, McConnell JD.

Prostate. 2000 Aug 1;44(3):193-203.

PMID:
10906735
17.

Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.

Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ.

Prostate. 2003 Aug 1;56(3):171-82.

PMID:
12772186
18.

Pygeum africanum for benign prostatic hyperplasia.

Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G.

Cochrane Database Syst Rev. 2002;(1):CD001044. Review.

PMID:
11869585
19.

Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Sutcliffe S, Grubb Iii RL, Platz EA, Ragard LR, Riley TL, Kazin SS, Hayes RB, Hsing AW, Andriole GL; Urologic Diseases in America Project.

BJU Int. 2012 Oct;110(7):1050-9. doi: 10.1111/j.1464-410X.2011.10867.x. Epub 2012 Mar 19.

20.

Supplemental Content

Support Center